glp-1 obesity drug news today sep 30 2025 september GLP-1 Drugs: 2025 Pulse Survey (U.S.) GLP-1 Agonists Weight Loss Drugs

I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance)

Novo Nordisk announced that its rebranded and reformulated oral GLP-1 medication, formerly known as Rybelsus, is now available in the U.S

Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials

Evidence-based comparison of retatrutide (GIP/GLP-1/glucagon triple agonist) and survodutide (GLP-1/glucagon dual agonist) for weight loss, MASH, and metabolic disease based on Phase 2 clinical trial data.

A natural drink mix that supports appetite control, metabolic balance, and digestive wellness through clinically backed plant compounds

This review examines the biological mechanisms underlying GLP-1 RA therapy in MASLD/MASH, analyzes the mechanistic distinctions between mono-, dual-, and triple agonists, and synthesizes current clinical evidence supporting their utilization in individuals with this condition.